Stéphane A. Régnier

734 total citations
37 papers, 533 citations indexed

About

Stéphane A. Régnier is a scholar working on Ophthalmology, Economics and Econometrics and Psychiatry and Mental health. According to data from OpenAlex, Stéphane A. Régnier has authored 37 papers receiving a total of 533 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Ophthalmology, 9 papers in Economics and Econometrics and 9 papers in Psychiatry and Mental health. Recurrent topics in Stéphane A. Régnier's work include Retinal Diseases and Treatments (9 papers), Migraine and Headache Studies (8 papers) and Retinal Imaging and Analysis (7 papers). Stéphane A. Régnier is often cited by papers focused on Retinal Diseases and Treatments (9 papers), Migraine and Headache Studies (8 papers) and Retinal Imaging and Analysis (7 papers). Stéphane A. Régnier collaborates with scholars based in Switzerland, United Kingdom and Denmark. Stéphane A. Régnier's co-authors include Jasper Huels, Felicity Allen, Vladimir Bezlyak, David B. Ridley, Jonathan Wright, Michael Larsen, Andrew Lotery, S. Aractingi, O. Heinzlef and Andreas Tietz and has published in prestigious journals such as PLoS ONE, Neurology and Nature Reviews Drug Discovery.

In The Last Decade

Stéphane A. Régnier

35 papers receiving 517 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Stéphane A. Régnier Switzerland 12 180 141 113 102 75 37 533
Elias Laurin Meyer Austria 13 80 0.4× 84 0.6× 86 0.8× 33 0.3× 57 0.8× 43 461
Hao Feng United States 10 82 0.5× 32 0.2× 76 0.7× 18 0.2× 44 0.6× 71 485
V. Taieb United Kingdom 11 112 0.6× 27 0.2× 24 0.2× 17 0.2× 41 0.5× 71 436
Raymond A. Harvey United States 12 50 0.3× 36 0.3× 34 0.3× 23 0.2× 22 0.3× 26 575
Pankaj Kumar India 13 227 1.3× 16 0.1× 41 0.4× 48 0.5× 16 0.2× 65 629
Emanuela Foglia Italy 13 73 0.4× 23 0.2× 25 0.2× 24 0.2× 45 0.6× 79 429
Juan A. Siordia United States 10 51 0.3× 23 0.2× 60 0.5× 82 0.8× 16 0.2× 21 442
Sarah Diamond United States 11 50 0.3× 8 0.1× 25 0.2× 58 0.6× 18 0.2× 24 510
Enrique Broseta Spain 12 105 0.6× 11 0.1× 37 0.3× 82 0.8× 10 0.1× 49 481
Hala Tamim Canada 14 167 0.9× 6 0.0× 31 0.3× 38 0.4× 43 0.6× 39 669

Countries citing papers authored by Stéphane A. Régnier

Since Specialization
Citations

This map shows the geographic impact of Stéphane A. Régnier's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Stéphane A. Régnier with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Stéphane A. Régnier more than expected).

Fields of papers citing papers by Stéphane A. Régnier

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Stéphane A. Régnier. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Stéphane A. Régnier. The network helps show where Stéphane A. Régnier may publish in the future.

Co-authorship network of co-authors of Stéphane A. Régnier

This figure shows the co-authorship network connecting the top 25 collaborators of Stéphane A. Régnier. A scholar is included among the top collaborators of Stéphane A. Régnier based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Stéphane A. Régnier. Stéphane A. Régnier is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Ren, Shijie, et al.. (2024). Issues, Challenges and Opportunities for Economic Evaluations of Orphan Drugs in Rare Diseases: An Umbrella Review. PharmacoEconomics. 42(6). 619–631. 3 indexed citations
2.
Barbanti, Piero, et al.. (2024). Impact of eptinezumab on work productivity beyond reductions in monthly migraine days: post hoc analysis of the DELIVER trial. Journal of Patient-Reported Outcomes. 8(1). 146–146.
3.
4.
Ismail, Zahinoor, Maı̈a Miguelez, Stéphane A. Régnier, et al.. (2024). Assessment of patient life engagement in schizophrenia using items from the Positive and Negative Syndrome Scale. Schizophrenia Research. 274. 337–344. 3 indexed citations
5.
6.
Schattenberg, Jörn M., Maria‐Magdalena Balp, B.S. Reinhart, et al.. (2023). NASHmap: clinical utility of a machine learning model to identify patients at risk of NASH in real-world settings. Scientific Reports. 13(1). 5573–5573. 7 indexed citations
7.
Dick, Katherine, John A. Schneider, Andrew Briggs, et al.. (2021). Mendelian randomization: estimation of inpatient hospital costs attributable to obesity. Health Economics Review. 11(1). 16–16. 2 indexed citations
8.
Hünger, Matthias, et al.. (2020). Mapping the Kansas City Cardiomyopathy Questionnaire (KCCQ) Onto EQ-5D-3L in Heart Failure Patients: Results for the Japanese and UK Value Sets. MDM Policy & Practice. 5(2). 3444620118–3444620118. 3 indexed citations
9.
10.
Feldman, Steven R., et al.. (2019). Patient-reported outcomes are important elements of psoriasis treatment decision making: A discrete choice experiment survey of dermatologists in the United States. Journal of the American Academy of Dermatology. 80(6). 1650–1657. 22 indexed citations
11.
12.
Régnier, Stéphane A., Michael Larsen, Vladimir Bezlyak, & Felicity Allen. (2015). Comparative efficacy and safety of approved treatments for macular oedema secondary to branch retinal vein occlusion: a network meta-analysis. BMJ Open. 5(6). e007527–e007527. 42 indexed citations
13.
Régnier, Stéphane A., et al.. (2015). Cost-effectiveness of ranibizumab versus aflibercept in the treatment of visual impairment due to diabetic macular edema: a UK healthcare perspective. ClinicoEconomics and Outcomes Research. 7. 235–235. 26 indexed citations
14.
Régnier, Stéphane A. & David B. Ridley. (2015). Forecasting market share in the US pharmaceutical market. Nature Reviews Drug Discovery. 14(9). 594–595. 9 indexed citations
15.
16.
17.
Régnier, Stéphane A. & Jasper Huels. (2013). Association Between Respiratory Syncytial Virus Hospitalizations in Infants and Respiratory Sequelae. The Pediatric Infectious Disease Journal. 32(8). 820–826. 126 indexed citations
18.
Régnier, Stéphane A. & Jasper Huels. (2013). Drug versus vaccine investment: a modelled comparison of economic incentives. Cost Effectiveness and Resource Allocation. 11(1). 23–23. 10 indexed citations
19.
20.
Régnier, Stéphane A.. (2013). What is the value of ‘me-too’ drugs?. Health Care Management Science. 16(4). 300–313. 31 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Elias Laurin Meyer Breakdown of academic impact, for papers by Hao Feng Breakdown of academic impact, for papers by V. Taieb Breakdown of academic impact, for papers by Raymond A. Harvey Breakdown of academic impact, for papers by Pankaj Kumar Breakdown of academic impact, for papers by Emanuela Foglia Breakdown of academic impact, for papers by Juan A. Siordia Breakdown of academic impact, for papers by Sarah Diamond Breakdown of academic impact, for papers by Enrique Broseta Breakdown of academic impact, for papers by Hala Tamim
Rankless by CCL
2026